ArticleInternational journal of molecular sciences2019
Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 80 citations in OpenAlex.
- Androgen Receptor (AR) Expression is Associated with an Immune-Cold Phenotype and Reduced Response to Immune Checkpoint Inhibitors in ER-Positive/HER2-Negative Breast Cancer.Annals of surgical oncology · 2026Article
- Development and evaluation of clinical models based on ultrasound, serum CA153 and molecular subtype in predicting the efficacy of neoadjuvant chemotherapy in breast cancer.Oncology letters · 2026Article
- Prognostic value of androgen receptor expression in ER-positive/HER2-negative breast cancer: evidence from a contemporary Chinese cohort.Frontiers in oncology · 2026Article
- Invasive Lobular Carcinoma Has Higher Immune Response Than Invasive Ductal Carcinoma in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers.World journal of oncology · 2025Article
- Clinical significance of androgen receptor in unilateral invasive breast cancer in women.European journal of medical research · 2025Article
- Regulation of Stromal Cells by Sex Steroid Hormones in the Breast Cancer Microenvironment.Cancers · 2024Review
- Enhanced cancer cell proliferation and aggressive phenotype counterbalance in breast cancer with high BRCA1 gene expression.Breast cancer research and treatment · 2024Article
- Emerging measurements for tumor-infiltrating lymphocytes in breast cancer.Japanese journal of clinical oncology · 2024Review
- Unveiling the Future of Oncology and Precision Medicine through Data Science.International journal of molecular sciences · 2024Article
- High Ki67 Gene Expression Is Associated With Aggressive Phenotype in Hepatocellular Carcinoma.World journal of oncology · 2024Article
- Immune Cytolytic Activity and Strategies for Therapeutic Treatment.International journal of molecular sciences · 2024Review
- A therapeutical insight into the correlation between circRNAs and signaling pathways involved in cancer pathogenesis.Medical oncology (Northwood, London, England) · 2024Review
- HighAmerican journal of cancer research · 2024Article
- Hormone-Dependent Cancers: New Aspects on Biochemistry and Molecular Pathology.International journal of molecular sciences · 2023Article
- Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.Discover oncology · 2023Article
- Biomarker Research in World Journal of Oncology.World journal of oncology · 2023Article
- Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.Breast cancer research : BCR · 2023Article
- High Mesothelin expression in pancreatic adenocarcinoma is associated with aggressive tumor features but not prognosis.American journal of cancer research · 2023Article
- Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress.Frontiers in oncology · 2023Review
- Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer.American journal of cancer research · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
Abstract
Estrogen receptor (ER) positive breast cancer (BC), the most abundant BC subtype, is notorious for poor response to neoadjuvant chemotherapy (NAC). The androgen receptor (AR) was reported to support estradiol-mediated ER activity in an in vitro system. Recently, ER-positive BC with fewer tumor infiltrating lymphocytes (TILs) was shown to have a better prognosis, opposite to the trend seen with ER-negative BC. We hypothesized that ER-positive BC with high expression of AR will have fewer TILs and an inferior response to NAC, but with a better prognosis. In both TCGA and METABRIC cohorts, AR expression was significantly higher in ER-positive BCs compared to ER-negatives (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.